Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Royalty Pharma plc

Royalty Pharma plc (RPRX) Stock Overview

Explore Royalty Pharma plc’s financial performance, market position, analyst ratings, and future outlook.

RPRX●NASDAQ
HealthcareMedical - Pharmaceuticals
$66.52
$0.66(0.98%)
U.S. Market opens in 5h 10m

Royalty Pharma plc (RPRX)

Meyka AI Score

Z

Key Financials

Market Cap29.6B
P/E Ratio27.72
EPS (TTM)$5.25
ROE0.12%
Fundamental Analysis

AI Price Forecasts

1 Month$67.95
3 Months$70.67
1 Year Target$64.60

RPRX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Royalty Pharma plc (NASDAQ: RPRX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Royalty Pharma plc's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of RPRX on the NASDAQ shows an RSI of 72.33, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $64.60 for the NASDAQ listing.

Key metrics behind Royalty Pharma plc's NASDAQ-traded stock include a P/E ratio of 27.72 and a market capitalization of 29.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of RPRX on the NASDAQ.

Price Performance (NASDAQ: RPRX)

1-Day Change
-0.98%
5-Day Change
2.62%
1-Month Change
16.38%
3-Month Change
13.85%
6-Month Change
34.47%
Year-to-Date (YTD) Change
72.15%
1-Year Change
78.34%
3-Year Change
142.07%
5-Year Change
74.55%
All-Time (Max) Change
49.48%

Contact Information

https://www.royaltypharma.com
212 883 0200
110 East 59th Street, New York, NY, 10022

Company Facts

1,000 Employees
IPO DateJun 16, 2020
CountryUS
Actively Trading

Frequently Asked Questions